Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC–MS/MS

Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1)

(2016) Pasi A. Jänne et al.   Clinical Lung Cancer

Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance

(2014) Brian Booth et al.   AAPS Journal

Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

(2013) Alan L. Ho et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice

(2010) Cathrine L. Denton et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

Challenges in urine bioanalytical assays: overcoming nonspecific binding

(2010) Allena Ji Ji et al.   Bioanalysis

Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations

(2009) Douglas M. Fast et al.   AAPS Journal

Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum

(2009) Philip Timmerman et al.   Bioanalysis